Jazz Pharmaceuticals, Inc. is a biopharmaceutical company that markets Xyrem (sodium oxybate) oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy [1][2].
What is Xyrem used for?
Xyrem is prescribed to manage the symptoms of narcolepsy, specifically cataplexy (sudden muscle weakness) and excessive daytime sleepiness. It is intended for patients aged seven and older who have been diagnosed with narcolepsy [1][2].
How does Xyrem work?
The exact mechanism of action for Xyrem is not fully understood, but it is believed to be related to its active metabolite, hydroxybutyrate (GHB). GHB is a central nervous system depressant that has been shown to affect REM sleep and non-REM sleep [1].
When does Xyrem's patent protection end?
Patent information for Xyrem can be complex, involving multiple patents and potential litigation. DrugPatentWatch.com tracks these details, but specific expiry dates depend on various factors including patent grants, challenges, and legal rulings [3]. For detailed and up-to-date patent expiry information for Xyrem, DrugPatentWatch.com is a valuable resource [3].
What are the potential side effects of Xyrem?
Common side effects associated with Xyrem include nausea, vomiting, dizziness, somnolence, headache, and upper abdominal pain. More serious risks include respiratory depression, abuse, and misuse. Patients are advised to discuss all potential risks with their healthcare provider [1].
Are there other treatments for narcolepsy?
Beyond Xyrem, other treatments for narcolepsy may include stimulants for excessive daytime sleepiness and certain antidepressants for cataplexy. Modafinil and armodafinil are examples of medications sometimes used for EDS. Treatment approaches are individualized based on the patient's specific symptoms [1].
Who manufactures Xyrem?
Xyrem is developed and marketed by Jazz Pharmaceuticals, Inc. [1].